Medtronic's Infuse Bone Graft Injuries Have Large Impact on Device MakerAug 30, 2013
Safety concerns swirling around Medtronic Inc.’s Infuse bone growth material have severely impacted the company’s future and certainly its current market dominance.
According to SeekingAlpha.com, Medtronic’s revenues from Infuse sales dropped a whopping 11 percent in the second quarter this year, spurred mostly by those concerns. An increasing number of spinal fusion surgery recipients have complained of serious and some life-threatening complications that have arisen after they’ve received the Infuse bone growth product.
Also contributing to the losses Medtronic is incurring because of Infuse is a rise in competitive products in the bone graft market, SeekingAlpha.com is reporting.
If you’ll recall from our previous reports, Infuse is a bone growth material that’s used in place of a traditional bone graft — usually from the hip bone — in a spinal fusion surgery. The U.S. Food and Drug Administration (FDA) has approved the use of Infuse in only certain spinal fusion surgeries, not including neck surgeries for example.
This exemption has not stopped surgeons from using Infuse for these purposes, and our previous accounts show that Medtronic is facing criticism for allegedly promoting the use of Infuse for unapproved off-label surgeries.
Other Infuse recipients have suffered equally serious complications, including nerve damage, chronic pain, and male sterility, according to our reports.